

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
20 November 2003 (20.11.2003)

PCT

(10) International Publication Number
WO 03/095472 A1

(51) International Patent Classification⁷: **C07J 73/00**

(21) International Application Number: PCT/HU03/00036

(22) International Filing Date: 7 May 2003 (07.05.2003)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
P0201584 10 May 2002 (10.05.2002) HU

(71) Applicant (for all designated States except US):
RICHTER GEDEON VEGYÉSZETI GYÁR RT.
[HU/HU]; Gyömrői út 19-21, H-1103 Budapest (HU).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **BARTHÓ, István**
[HU/HU]; Alsómalom u. 3, H-1164 Budapest (HU).
HÉRINÉ, BERTA, Mónika [HU/HU]; Füredi út 52-54,
H-1144 Budapest (HU). **DÉVÉNYI, Tamás** [HU/HU];
Villányi út 78/C, H-1118 Budapest (HU). **HANTOS,**

Gábor [HU/HU]; Pára u. 6, H-1108 Budapest (HU).
OLASZ, Katalin [HU/HU]; Örmester u. 7, H-1163
Budapest (HU). **PÉCSNÉ, RÁZSÓ, Ágnes** [HU/HU];
Kassai tér 10, H-1142 Budapest (HU).


(74) Common Representative: **RICHTER GEDEON VEGYÉSZETI GYÁR RT.**; Gyömrői út 19-21, H-1103 Budapest (HU).

(81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.


(84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO,

[Continued on next page]

(54) Title: PROCESS FOR DEHYDROGENATION OF AZAANDROSTANE COMPOUNDS



(I)



(II)

(57) Abstract: The invention relates to a process for the production of compounds of general formula (I), wherein R₁ is a -NH-tert-butyl group or a 4-methyl-piperidino group, by bioconversion of compounds of general formula (II), wherein R₁ is as described above, using a biocatalyst having steroid- Δ^1 -dehydrogenase enzyme activity, wherein the activity of the enzyme needed for the bioconversion is produced by induction.



SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Declaration under Rule 4.17:

- *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii)) for the following designations AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW, ARIPO patent (GH, GM,*

KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG)

Published:

- *with international search report*

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

PROCESS FOR DEHYDROGENATION OF AZAANDROSTANE COMPOUNDS

BACKGROUND OF THE INVENTION

Field of the Invention

The present invention relates to a novel process for dehydrogenation of
5 azaandrostandane compounds.

Related Art

The 4-azasteroids are well known specific inhibitors of the testosterone 5 α -
reductase enzyme. According to previously published data it is apparent that the introduction
of the double bond in the C-1,2 position of the molecule is necessary for obtaining the
10 desired effect.

There are both synthetic and biochemical methods for introducing a double bond
into the C-1,2 position of 4-azasteroids.

One of the synthetic methods is the introduction of the Δ^1 double bond with
benzeneselenic anhydride in boiling chlorobenzene (for example, Patent No. EP 155 096).

15 Alternatively, dehydrogenation can be carried out with kinones (*e.g.* 2,3-dichloro-
5,6-dicyano-benzokinone) in the presence of silylating agents (*e.g.*, bis-trimethyl-silyl-
trifluoro-acetamide) (Patent No. EP 298 652).

According to processes described in EP 428 366 and EP 655 459 the 2-halogen
derivative of a steroid can be used as an intermediate to introduce the C-1,2 double bond.
20 Patent No. CA 2 271 974 discloses a process in which the Δ^1 double bond is introduced into
an aza-steroid using a 2,2-dibromo-aza-steroid compound as an intermediate.

In another process, 2-halogen derivatives are prepared from the appropriate
unsubstituted 4-aza compound via a trialkylsilyl-trifluoro-methanesulfonate intermediate
with iodine or trimethylsilyl chloride and iodine (Patent No. EP 473 226). The desired Δ^1
25 compound is obtained from this 2-halogen-4-aza derivative with potassium *tert*-butoxide in
dimethylformamide solution in about 60% yield.

These synthetic methods require extremely aggressive reaction conditions that have
several disadvantages. First, impurities are formed. Second, the impurities, although formed

- 2 -

in low concentration (below 0.1%), are not characterized, and some might be toxic. In addition, some of the applied reagents are carcinogenic, flammable, demand completely dry circumstances, or are highly corrosive, and therefore are environmental hazards.

5 In contrast, the conditions required for biochemical methods for Δ^1 dehydrogenation are gentle and produce fewer and less environmentally hazardous by-products. As a consequence, the formation of toxic compounds is less likely. Moreover, instead of two synthetic steps, the transformation can be carried out in a single step.

10 Although the Δ^1 -dehydrogenation of steroids is well known in the literature (*Microbial Transformations of Steroids*, Charney, W., Herzog, H. L., Academic Press, New York, London, (1967)), there are very few examples of the microbiological introduction of a double bond into the C-1,2 position of aza-steroids, probably because of the well known antibacterial effect of aza-steroids (*J. Bacteriol.*, 93(2), 627-35 (1967); *Steroids*, 27(4), 525-41 (1976); *Chem. Ind.*, 52, 1660-1 (1970)).

15 The microbial introduction of a Δ^1 double bond into 12a-aza compounds has been accomplished with *Nocardia sp.* and *Arthrobacter sp.* strains (Mazur *et al.*, *J. Org. Chem.*, 28(9), 2442-3 (1963)). According to Mazur *et al.*, the conversion of 12a-aza-C-homo-1,4-pregnadiene-3,12,20-trione could be realized at 0.29 g/L concentration with a 62% yield; the conversion of 12a-aza-17 α -hydroxy-C-homo-1,4-pregnadiene-3,12,20-trione could be realized at 0.17 g/L concentration with a 17% yield; and the conversion of 12a-aza-C-homo-20 5 α -pregn-1-ene-3,12,20-trione could be realized at 0.29 g/L concentration with a 26% yield.



25 Similarly, *Arthrobacter sp.* and *Nocardia sp.* strains have been used to Δ^1 -dehydrogenate the 17-N-tert-butylcarbonyl-4-azaandrostan-3-one substrate at 0.1-1.0 g/L concentration with a 20-80% yield (Patent No. EP 786 011). In this method, the Δ^1 -dehydrogenase enzymes of the above strains were induced by the addition of hydrocortisone, the separated biomass was suspended in a buffer (pH=6-8) saturated with organic solvent and the bioconversion was performed in the presence of menadione or phenazine methosulfate. The bioconversion was carried out in a small volume. In the only disclosed example the conversion was carried out for 3 days in a volume of 20 ml at 0.26 g/L substrate concentration with a 60% yield. However, for industrial realization, one must determine the 30 appropriate concentration level and scale up the procedure. According to our experiments,

- 3 -

when this procedure is scaled up, the conversion drops drastically. Therefore, a fundamental modification of this process is essential for industrial realization.

SUMMARY OF THE INVENTION

The aim of the present invention is to provide a bioconversion process that avoids the disadvantages of wholly synthetic methods while achieving industrial realization. More specifically, the invention relates to a process for the production of compounds of general formula (I), wherein R_1 is a -NH-tert-butyl group or a 4-methyl-piperidino group, by bioconversion of compounds of general formula (II), wherein R_1 is as described above, using a biocatalyst having steroid- Δ^1 -dehydrogenase enzyme activity, wherein the activity of the enzyme needed for the bioconversion is produced by induction.



In one preferred embodiment, the present invention encompasses a method for producing a compound of formula I, comprising the steps of:

- a) preparing a culture of a biocatalyst or an extract of a biocatalyst;

- 4 -

- b) adding to the culture or extract an inducer of steroid- Δ^1 -dehydrogenase activity;
- c) adding to the culture or extract an electron carrier, a stabilizer, and a compound of formula II; and
- 5 d) incubating the culture or extract for a time sufficient for bioconversion of the compound of formula II to the compound of formula I to occur.

In another preferred embodiment, the present invention encompasses a method for producing a compound of formula I, comprising the steps of:

- 10 a) preparing a culture of a biocatalyst or an extract of a biocatalyst, wherein said culture or extract has a volume of at least about 1 L;
- b) adding to the culture or extract an inducer of steroid- Δ^1 -dehydrogenase;
- c) adding to the culture or extract an electron carrier, a stabilizer, a complexing agent or emulsifier, and a compound of formula II; and
- 15 d) incubating the culture or extract for a time sufficient for bioconversion of the compound of formula II to the compound of formula I to occur.

In another preferred embodiment, the present invention encompasses a method for producing a compound of formula I, comprising the steps of:

- a) preparing a culture of a biocatalyst or an extract of a biocatalyst;
- b) adding to the culture or extract an inducer of steroid- Δ^1 -dehydrogenase;
- 20 c) adding to the culture or extract an electron carrier at a concentration of about 0.05 to about 3.5 g/L and a stabilizer at a concentration of about 0.01 to about 0.1 g/L and a compound of formula II; and
- d) incubating the culture or extract for a time sufficient for bioconversion of the compound of formula II to the compound of formula I to occur;
- 25 provided that an oxygen scavenger is not added to the culture or extract.

DETAILED DESCRIPTION OF THE INVENTION

The invention relates to a process for the production of compounds of general formula (I), wherein R_1 is a -NH-tert-butyl group or a 4-methyl-piperidino group, by bioconversion of compounds of general formula (II), wherein R_1 is as described above, using
30 a biocatalyst having steroid- Δ^1 -dehydrogenase enzyme activity, by inducing the activity of

- 5 -

the enzyme, maintaining the activity of the enzyme at the necessary level by adding a stabilizer, promoting the continuous dissolution of the substrate by adding a complexing agent, and completing the conversion by adding an electron carrier.

5 The term bioconversion is defined as the conversion of compound (II) to compound (I) through the use of a biocatalyst such that at least a measurable amount of compound (I) is produced.

10 The term biocatalyst is defined as any microorganism that contains or can be induced to contain steroid- Δ^1 -dehydrogenase enzyme activity. Examples of biocatalysts include, but are not limited to, bacteria, fungi and animal cells. The method of the invention may be carried out with the above mentioned and known methods of preparing a biocatalyst (e.g., intact cells, cell free extracts, immobilized preparations thereof). For example, intact cells of *Arthrobacter simplex* can be used by incubating a submerged culture in a liquid medium containing a carbon source, preferably glucose in a concentration of 1-15 g/L, a nitrogen source, such as yeast extract in a concentration of 1-10 g/L, and inorganic salts. The culture is incubated at 25-38°C, preferably at 35°C, for 20-72 hours. A solution containing the agent(s) inducing the activity of the steroid Δ^1 -dehydrogenase enzyme is then added. For those skilled in the art, it will be apparent that the process of the invention can be carried out with other biocatalysts having steroid- Δ^1 -dehydrogenase activity, such as living or resting intact cells, cell lysate and free or immobilized preparations (*J. Am. Chem. Soc.*, 108, 6732, (1986); *Chem. Rev.*, 92, 1071-1140 (1992)).

20 The strains *Arthrobacter sp.* and *Nocardia sp.* may be used in the methods of the invention. Moreover, although azasteroids have an antibacterial effect, surprisingly we found that, in addition to the *Arthrobacter sp.* and *Nocardia sp.*, strains belonging to the genera *Bacillus* and *Mycobacterium* were able to Δ^1 -dehydrogenate 4-azasteroids. Specific strains that may be used include, but are not limited to, *Arthrobacter simplex* (ATCC 6946), *Bacillus subtilis* (NRRL B-558), *Bacillus sphaericus* (ATCC 7054), *Bacillus lentus* (ATCC 13805), *Nocardia corallina* (ATCC 4275), and *Mycobacterium sp.* (NRRL B-3683). The production of cell free extracts of steroid- Δ^1 -dehydrogenase, as well as the immobilization of intact cells or cell free extracts from all of these strains is widely described in the literature (*J. Am. Chem. Soc.*, 108, 6732, (1986); *Chem. Rev.*, 92, 1071-1140 (1992)).

30 The activity of the Δ^1 -dehydrogenase enzyme is induced by a known method, such as the addition of hydrocortisone. Other inducers that may be used include, but are not

limited to, prednisolone, prednisone, cortisone, and androsta-1,4-diene-3,17-dione. However, the activity of the enzyme decreases over the course of time due to the consumption of the coenzyme or the activity of proteolytic enzymes. Several known methods may be used to maintain the activity of the enzyme; such as chemical modification
5 or immobilization of the enzyme, packing the enzyme into a liposome capsule, and the use of additives (sugar derivatives: polyols, esters; amino acids, proteins, dextrans, lecitin, DMSO). *World Biotech. Rep.*, 1, 379-390 (1984); Patent No. JP 62-096084; *Biotechnol. Bioengineer.* 75, 615-618 (2001); Patent Nos. JP 96196330, JP 89185636, JP 86253336.

In the absence of an induction agent, the activity of the Δ^1 -dehydrogenase enzyme
10 may drop. To compensate for this decrease, it is necessary to add more of the induction agent. For a bioconversion that continues for several days the induction agent must be added continuously in order to maintain the necessary concentration of induction agent.

The induction of the enzyme may be performed by any known method, such as by addition of a methanolic solution of hydrocortisone into the culture in a concentration of
15 about 10 to about 100 mg/L. Since hydrocortisone is enzymatically degraded, its induction effect decreases continuously. Therefore, to maintain the high enzyme activity necessary for bioconversion, repeated addition of hydrocortisone (altogether 2.7 g/L) is required. The frequency of hydrocortisone administration is dependent on the rate of enzymatic breakdown of the hydrocortisone. Preferably, hydrocortisone is administered once per day.

According to a more preferred method, the induction can be performed by addition
20 of steroids that are resistant to degradation by bacterial enzymes, such as 9α -hydroxylase, and that are substrates of the Δ^1 -dehydrogenase enzyme, or that already have a Δ^1 -double bond, in a concentration of about 10 to about 100 mg/L.

Surprisingly, we have had excellent results with the bioconversion process by, after
25 the induction of the activity of the Δ^1 -dehydrogenase enzyme, adding a stabilizer to maintain the appropriate level of enzyme, adding a complexing agent to promote continuous dissolution of the substrate, and adding a known electron carrier to make the bioconversion complete.

It was found that compounds that cannot induce the activity of Δ^1 -dehydrogenase
30 enzyme can stabilize the enzymes already present in the system and preserve their Δ^1 -dehydrogenase activity for a prolonged time without any other intervention. 5α -androstanediol or its 17-methyl derivative, 13-ethyl-gon-4-ene-3,17-dione or its acetoxy or

hydroxy derivative, 9,11-dehydro-hydrocortisone or its acetate derivative, estr-4-ene-3,17-dione or its acetoxy or 11 α -hydroxy derivative, and 13-ethyl-10,11 α -dihydroxy-gon-4-ene-3,17-dione, which are added to stabilize the enzyme, can preserve the activity when added in a final concentration of about 10 to about 100 mg/L. The most preferred stabilizer is 13-ethyl-10,11 α -dihydroxy-gon-4-ene-3,17-dione, which maintains the induction effect at 50 mg/L concentration for days with no loss of dehydrogenase activity experienced for 3-5 weeks when the culture is stored at 5-12°C.

The vast majority of steroids are poorly soluble in water. However, the addition of a steroid substrate dissolved in an organic solvent would not provide sufficient bioavailability in the bioconversion system. Thus, emulsifiers or complexing agents may be used in the method of the present invention to increase biological accessibility of the substrate in bioconversions performed in aqueous systems. An emulsifier, such as polyoxyethylene-sorbitan-monooleate (*e.g.*, TWEEN-80) (Patent No. HU 216 874) in a concentration of about 0.5 to about 4 g/L may be used. Other emulsifiers that may be used include, but are not limited to, TEGIN[®] and TAGAT[®] (Goldschmidt Chemical Corp.). Alternatively, a complexing agent, for example, α -, β - and γ -cyclodextrins and cyclodextrin derivatives, may be used advantageously (*Appl. Microbiol. Biotechnol.*, 32, 556-559 (1990); "Cyclodextrins and their Industrial Uses" ed. D.Duchene, Editions de Sante, Paris, (1987); *Appl. Microbiol. Biotechnol.*, 58, 393-399 (2002); Patent No. RU 2 039 824). Another complexing agent that may be used is TAMOL[®] (BASF).

In the process of the present invention, cyclodextrin and cyclodextrin derivatives may be added to the medium in a concentration of about 1 to about 50 g/L. Methyl- β -cyclodextrin and hydroxypropyl- β -cyclodextrin are preferred. A cyclodextrin derivative is defined as a cyclodextrin modified by one or more moieties such that the modified cyclodextrin maintains the ability to act as a complexing agent. Moieties that may be used include methyl, dimethyl, random-methyl, carboxy-methyl, and succinyl.

Since the enzymatic conversion of the substrate of general formula (II) to the product of general formula (I) is an equilibrium reaction, to accomplish the conversion and to increase the reaction rate, according to the process of the invention, electron carriers are used, such as naphthoquinone, menadione, menadione bisulfite and phenazine methosulfate. Preferably, menadione bisulfite is used in a concentration of about 0.05 to about 3.5 g/L, more preferably in a concentration of at least 0.1, 0.5, 1.0, 1.5, or 2.0 g/L, even more

- 8 -

preferably in a concentration of about 3.1 g/L. The addition can be performed in one batch or in several portions, but is preferably added in four portions. Preferably, the electron carrier is added at intervals of 18-24 hours.

Note that this element of the process of the invention is quite surprising, since by increasing the amount of the applied electron carrier by two orders of magnitude over the usual amount, the conversion rate can be increased substantially, without using further additives to remove the formed toxic oxygen species. The published preconception was that the use of larger amounts of electron carrier would cause the formation of toxic oxygen derivatives that would have to be removed by oxygen scavengers. See the process described in US Patent No. 4,749,649.

Applying any one of the three elements of this invention (stabilizer, complexing agent, electron carrier) individually results in a 10-15% increase in the bioconversion over that seen in its absence. However, the combined use of all of them surprisingly gives not a simple additive effect but a synergic effect resulting in a bioconversion of more than 90%. While the bioconversion can be carried out in any volume, the present invention advantageously is carried out in a volume of at least 1 L, preferably at least 5 L.

The bioconversion can be carried out for a length of time sufficient for at least a measurable amount of bioconversion to occur, preferably at least 24 hours, more preferably at least 72 hours.

The activity of the induced culture can be increased by known methods, for example, by producing a high cell concentration. This can be accomplished by nutrient feeding, repeated inoculation or separation of the cells and resuspending them in a reduced volume. The cells can be resuspended in a buffer solution of pH 6-8, in a buffer solution saturated with organic solvent, or in fresh medium. According to a preferred method, the cells are separated and resuspended in a fresh medium containing the above mentioned ingredients so as to reach five to ten fold concentration. The substrate of general formula (II) is added to this culture of high activity in an ethanolic solution, in about 0.2 to about 2 g/L concentration, preferably in about 1 g/L final concentration.

The following examples are illustrative, but not limiting, of the methods of the present invention. Other suitable modifications and adaptations of the variety of conditions and parameters normally encountered in synthetic chemistry and bioconversion and which are obvious to those skilled in the art are within the spirit and scope of the invention.

The active ingredient content of the crystalline products obtained in the following examples was determined by HPLC.

The conditions of the measurement were as follows:

Column: LiChroCART 250-4, LiChrospher 100 CN (5 μ m)

5 Eluent: tetrahydrofuran : water = 30:60

Flow speed: 0.7 ml/min

Injected volume: 20 μ L

Detection: UV, 210 nm

Temperature: 60 °C

10

EXAMPLE 1

Arthrobacter simplex (ATCC 6946) culture was maintained on solid medium of the following composition:

15

Ingredient	g/L
Tryptic digest of casein	10
Yeast extract	1
NaCl	5
MgSO ₄ ·7H ₂ O	0.25
CaCl ₂ ·2H ₂ O	0.07
Agar	20
pH adjusted to 7.1-7.2, sterilized at 121°C for 40 minutes	

The inoculated medium was incubated at 32°C for 4 days, then stored at 4-10°C for another 30 days to start cultures. In order to produce vegetative cultures one agar slope was washed and transferred into 100 mL medium of the following composition, which was
20 sterilized in a 500 mL Erlenmeyer flask:

- 10 -

Ingredient	g/L
Yeast extract (Quest)	5.4
Dextrose	3
pH adjusted to 6.7 – 6.8 with 10% NaOH solution	
Sterilized at 121°C for 30 minutes	

The culture was incubated at 32°C for 24 hours on a rotary shaker at 200 rpm, then transferred into 5 L medium of the following composition, which was sterilized in a 9 L jar fermenter:

5

Ingredient	g/L	Notice
Dextrose	2	Sterilized separately in an aqueous solution of 500 g/L, added prior to inoculation
Yeast extract (Quest)	8	
NH ₄ Cl	10.9	
(NH ₄) ₂ SO ₄	0.5	
K ₂ HPO ₄	2.25	
KH ₂ PO ₄	0.75	
MgSO ₄ ·7·H ₂ O	2.38	
CaCl ₂ ·2 H ₂ O	0.29	
Antifoam Struktol SB2020	0.062	
Sterilized at 121°C for 40 minutes		
pH adjusted after sterilization to 6.1-6.2 with 20% NaOH solution		

The cultivation was performed at 35°C at 200 rpm and an air flow rate of 40 L/h. The production of Δ^1 -dehydrogenase enzyme was induced after 20 hours of cultivation by the addition of 500 mg of hydrocortisone dissolved in methanol. After 8 hours of induction the culture was centrifuged at 4800 rpm, the supernatant was discarded, and the approximately 100 mL cell concentrate was suspended in 500 mL fresh medium. This operation was repeated eight times giving altogether 4 L of biocatalyst.

10

- 11 -

The bioconversion was performed in the above mentioned jar fermenter at 30°C at 250 rpm and an air flow rate of 60 L/h.

The formation of Δ^1 -dehydrogenase enzyme was induced for a second time by the addition of 250 mg of hydrocortisone. After 2 hours, 250 mg of 13-ethyl-10,11 α -dihydroxy-gon-4-ene-3,17-dione was added in a methanolic solution.

The dissolution of the substrate was promoted by addition of 120 g of hydroxypropyl- β -cyclodextrin. 800 mg of 17 β -tert-butylcarbamoyl-4-azaandrostane-3-one substrate was added in an ethanolic solution to the mixture.

After the addition of the substrate, 8 g of menadione bisulfite, an electron carrier, was added in four portions of 2 g each, after intervals of 19, 20, and 24 hours, respectively. After addition of each portion of the electron carrier the air flow rate was increased by 20% of the original one: providing dissolved oxygen levels of 21, 25, 30 and 36% of air saturation. After 72 hours of bioconversion the culture was extracted with an equivalent volume of chloroform and the organic layer was concentrated to dryness.

The obtained crude crystalline product was 1315 mg, which contained 755 mg of 17 β -tert-butyl-carbamoyl-4-azaandrost-1-ene-3-one (94.4% conversion). The content of the active ingredient of the obtained crystalline product was determined by HPLC as described above.

EXAMPLE 2

The process described in Example 1 was applied, but 800 mg 4-methyl-1-[(5 α ,17 β)-3-oxo-4-azaandrostane-17-yl]-carbonyl]-piperidine was used as substrate.

The obtained crude crystalline product was 1422 mg, which contained 488 mg of 4-methyl-1-[(5 α ,17 β)-3-oxo-4-azaandrost-1-ene-17-yl]-carbonyl]-piperidine as product (61% conversion).

EXAMPLE 3

The process described in Example 1 was applied for each of the following stabilizers: 5 α -androstane-3 α ,17 β -diol and its 17-methyl derivative, 13-ethyl-4-gonene-3,17-dione

and its acetoxy and 11 α -hydroxy derivatives, 9,11-dehydro-hydrocortisone and its acetate derivative, 4-estren-3,17-dione and its acetoxy and 11 α -hydroxy derivatives.

The obtained crude crystalline products (in the order of the above compounds) were: 1315, 1611, 1665, 1412, 1189, 1653, 1312, 1425, 1222, 1345 mg; which contained
5 611, 288, 318, 555, 297, 411, 428, 371, 387, 424 mg of 17 β -tert-butyl-carbamoyl-4-azaandrost-1-ene-3-one, respectively. These correspond to 76, 36, 40, 69, 37, 51, 54, 46, 48, 53% conversion, respectively.

EXAMPLE 4

A culture of *Mycobacterium* sp. (NRRL B-3683) microorganism was prepared by
10 prior art methods, then the process described in Example 1 was applied to accomplish the bioconversion.

The obtained crude crystalline product was 1616 mg, which contained 36 mg of 17 β -tert-butyl-carbamoyl-4-azaandrost-1-ene-3-one (4.5% conversion).

EXAMPLE 5

15 A culture of *Bacillus subtilis* (NRRL B-558) microorganism was prepared by prior art methods, then the process described in Example 1 was applied to accomplish the bioconversion.

The obtained crude crystalline product was 1325 mg, which contained 14.4 mg of 17 β -tert-butyl-carbamoyl-4-azaandrost-1-ene-3-one (1.8% conversion).

20

EXAMPLE 6

To a culture of *Arthrobacter simplex* (ATCC 6946) microorganism (80 L, optical density of 18-25), which was prepared by prior art methods, 8 g of hydrocortisone was added in a methanolic solution to accomplish the induction of Δ^1 -dehydrogenase enzyme.

The fermentation was performed at 35°C with 200 rpm and an air flow rate of 960
25 L/h. Occasional foaming was suppressed by addition of Struktol SB2020 antifoaming agent.

- 13 -

A culture of 5000-8000 U/L activity was used to start the dehydrogenation of dihydrofinasteride. The induced culture was cooled to 30°C and 80 g of dihydro-finasteride was added in 800 ml of ethanol. The pH was adjusted to 7.5-7.7 by addition of 200 g/L NaOH or 100 g/L H₃PO₄ solutions, while keeping the agitation and the air flow rate constant. After the completion of the conversion the culture was extracted with ethyl acetate and the product was isolated by known methods.

The obtained crude crystalline product was 166 g, which contained 6.8 g of 17β-tert-butyl-carbamoyl-4-azaandrost-1-ene-3-one (8.5% conversion).

EXAMPLE 7

The process described in Example 6 was applied, but the formation of Δ¹-dehydrogenase enzyme was stabilized in addition to the induction. The hydrocortisone, which is the most advantageous inducer of the enzyme, can be metabolized by the high cell density culture, and this can lead to the gradual inactivation of the already formed enzyme. According to our experiments this inactivation was avoided by adding, in addition to hydrocortisone, 6 g of 13-ethyl-10,11α-dihydroxy-gon-4-ene-3,17-dione, which is non-inductive by itself, in methanolic solution at the beginning of the induction.

The obtained crude crystalline product was 138 g, which contained 24.96 g of 17β-tert-butyl-carbamoyl-4-azaandrost-1-ene-3-one (31.2% conversion).

EXAMPLE 8

The process described in Example 6 was applied, but before addition of the substrate 6000 g of sterilized, 40% (w/w) 2-hydroxypropyl-beta-cyclodextrin solution was added in order to promote the dissolution of the substrate.

The obtained crude crystalline product was 177 g, which contained 13.8 g of 17β-tert-butyl-carbamoyl-4-azaandrost-1-ene-3-one (11.1% conversion).

- 14 -

EXAMPLE 9

The process described in Example 6 was applied, but after addition of the substrate 64 g of menadione bisulfite was added in 360 ml of sterilized water, as electron carrier.

5 The obtained crude crystalline product was 121 g, which contained 22.3 g of 17 β -tert-butyl-carbamoyl-4-azaandrost-1-ene-3-one (17.8% conversion).

EXAMPLE 10

The process described in Example 6 was applied, but the methods described in examples 7 and 8 were also adopted.

10 The obtained crude crystalline product was 169 g, which contained 43.8 g of 17 β -tert-butyl-carbamoyl-4-azaandrost-1-ene-3-one (35% conversion).

EXAMPLE 11

The process described in Example 6 was applied, but the methods described in examples 7 and 9 were also adopted.

15 The obtained crude crystalline product was 151 g, which contained 35 g of 17 β -tert-butyl-carbamoyl-4-azaandrost-1-ene-3-one (28% conversion).

EXAMPLE 12

The process described in Example 6 was applied, but the methods described in Examples 8 and 9 were also adopted.

20 The obtained crude crystalline product was 187 g, which contained 27.5 g of 17 β -tert-butyl-carbamoyl-4-azaandrost-1-ene-3-one (22% conversion).

EXAMPLE 13

The process described in Example 6 was applied, but the methods described in Examples 7, 8 and 9 were also adopted.


- 15 -

The obtained crude crystalline product was 154 g, which contained 64 g of 17 β -tert-butyl-carbamoyl-4-azaandrost-1-ene-3-one (80% conversion).

- 16 -

WHAT IS CLAIMED IS:

1. A method for producing a compound of formula I




5

wherein R_1 is -NH-tert-butyl or 4-methyl-piperidino;

comprising the steps of:

- a) preparing a culture of a biocatalyst or an extract of a biocatalyst;
- b) adding to the culture or extract an inducer of steroid- Δ^1 -dehydrogenase activity;
- c) adding to the culture or extract an electron carrier, a stabilizer, and a compound of formula II;

10



15 and

- d) incubating the culture or extract for a time sufficient for bioconversion of the compound of formula II to the compound of formula I to occur.

2. The method of claim 1, wherein said biocatalyst is a bacteria selected from the group consisting of *Arthrobacter* and *Nocardia*.

20

3. The method of claim 2, wherein said bacteria is *Arthrobacter simplex*.

- 17 -

4. The method of claim 1-3, wherein said biocatalyst is a bacteria selected from the group consisting of *Bacillus* and *Mycobacterium*.

5. The method of claim 1-4, wherein said inducer is hydrocortisone.

5

6. The method of claim 5, wherein said hydrocortisone is added at a concentration of about 10 to about 100 mg/L.

7. The method of claim 1-6, wherein said electron carrier is selected from the group consisting of naphthoquinone, menadione, menadione bisulfite, and phenazine methosulfate.

10

8. The method of claim 7, wherein said electron carrier is added at a concentration of about 0.05 to about 3.5 g/L.

9. The method of claim 1-8, wherein said stabilizer is selected from the group consisting of 5 α -androstane-diol or its 17-methyl derivative, 13-ethyl-gon-4-ene-3,17-dione or its acetoxy or hydroxy derivative, 9,11-dehydro-hydrocortisone or its acetate derivative, estr-4-en-3,17-dione or its acetoxy or hydroxy derivative, and 13-ethyl-10,11 α -dihydroxy-gon-4-ene-3,17-dione.

20

10. The method of claim 9, wherein said stabilizer is added at a concentration of about 10 to about 100 mg/L.

11. The method of claim 1-10, wherein said compound of formula II is added at a concentration of about 0.2 to about 2 g/L.

25


12. The method of claim 1-11, wherein said complexing agent is a cyclodextrin or a cyclodextrin derivative selected from the group consisting of α -cyclodextrin, β -cyclodextrin, γ -cyclodextrin, methyl- β -cyclodextrin, and hydroxypropyl- β -cyclodextrin.

30

13. The method of claim 12, wherein said cyclodextrin or cyclodextrin derivative is added at a concentration of about 1 to about 50 g/L.

- 18 -

14. A method for producing a compound of formula I




5

wherein R₁ is -NH-tert-butyl or 4-methyl-piperidino;

comprising the steps of:

- a) preparing a culture of *Arthrobacter simplex*;
- b) adding to the culture hydrocortisone as an inducer of steroid- Δ^1 -
 10 dehydrogenase activity;
- c) adding to the culture 13-ethyl-10,11 α -dihydroxy-gon-4-ene-3,17-dione as a stabilizer, menadione bisulfite as an electron carrier, hydroxypropyl- β -cyclodextrin as a complexing agent, and a compound of formula II;



15

and

- d) incubating the culture for a time sufficient for bioconversion of the compound of formula II to the compound of formula I to occur.

INTERNATIONAL SEARCH REPORT

Internat	Application No
PCT/HU	03/00036

A. CLASSIFICATION OF SUBJECT MATTER
 IPC 7 C07J73/00

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
 IPC 7 C07J

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, WPI Data, PAJ; CHEM ABS Data, BEILSTEIN Data

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 96 12034 A (POLI IND CHIMICA SPA ;POLI STEFANO (IT); MAGNI AMBROGIO (IT); GRIS) 25 April 1996 (1996-04-25) claim 1; example 1 -----	1-14

☐

Further documents are listed in the continuation of box C.

☒

Patent family members are listed in annex.

* Special categories of cited documents :

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

- *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- *&* document member of the same patent family

Date of the actual completion of the international search

25 August 2003

Date of mailing of the international search report

03/09/2003

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
 NL - 2280 HV Rijswijk
 Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
 Fax: (+31-70) 340-3016

Authorized officer

Seelmann, I

INTERNATIONAL SEARCH REPORT

Information on patent family members

Internat

Application No

PCT/HU 03/00036

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9612034	A	25-04-1996	IT 1270660 B 07-05-1997
			AT 191508 T 15-04-2000
			AT 224451 T 15-10-2002
			AU 3805095 A 06-05-1996
			DE 69516162 D1 11-05-2000
			DE 69516162 T2 14-09-2000
			DE 69528296 D1 24-10-2002
			DK 922770 T3 27-01-2003
			WO 9612034 A1 25-04-1996
			EP 0786011 A1 30-07-1997
			EP 0922770 A2 16-06-1999
			ES 2106698 T1 16-11-1997
			ES 2184192 T3 01-04-2003
			PT 786011 T 31-07-2000
			PT 922770 T 31-01-2003
			TR 960311 A2 21-06-1996
